 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...36373839404142434445464748» |
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) (clinicaltrials.gov) - Sep 5, 2017
P2, N=80, Not yet recruiting, Sponsor: Shenzhen People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 29, 2017
P2, N=45, Not yet recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial: A Study To Test The Effect Of Apatinib On P450 Enzymes (clinicaltrials.gov) - Aug 9, 2017
P1, N=20, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Jul 11, 2017
P2, N=51, Recruiting, Sponsor: Zhejiang Cancer Hospital
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Jun 19, 2017
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial primary completion date: Jan 2017 --> May 2018
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (clinicaltrials.gov) - Jun 19, 2017
P1/2, N=63, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial primary completion date: Jan 2017 --> May 2018 Trial primary completion date: May 2017 --> May 2018
- |||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Monotherapy, Metastases: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) - Jun 19, 2017
P3, N=216, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial primary completion date: May 2017 --> May 2018 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov) - May 24, 2017
P2, N=128, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer (clinicaltrials.gov) - May 15, 2017
P2, N=48, Not yet recruiting, Sponsor: Zhou Fuxiang
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, P1 data, Trial primary completion date, Metastases: A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Apr 26, 2017
P1, N=16, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2017
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: EASE: An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 26, 2017
P2, N=52, Recruiting, Sponsor: Changzhou Cancer Hospital of Soochow University
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Enrollment change, Trial primary completion date: Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) (clinicaltrials.gov) - Apr 25, 2017
P2/3, N=233, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=318 --> 233 | Trial primary completion date: Dec 2017 --> Apr 2017
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients (clinicaltrials.gov) - Apr 25, 2017
P1, N=6, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | N=318 --> 233 | Trial primary completion date: Dec 2017 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases (clinicaltrials.gov) - Apr 25, 2017
P2, N=40, Not yet recruiting, Sponsor: Affiliated Hospital of Hebei University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) - Mar 30, 2017
P2, N=38, Not yet recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (clinicaltrials.gov) - Mar 22, 2017
P2, N=90, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- ||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Mar 16, 2017
P2, N=118, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (clinicaltrials.gov) - Feb 23, 2017
P2, N=90, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA (clinicaltrials.gov) - Jan 26, 2017
P2, N=74, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Monotherapy, Metastases: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) - Jan 11, 2017
P3, N=216, Not yet recruiting, Sponsor: Advenchen Laboratories, LLC
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0303? (clinicaltrials.gov) - Jan 11, 2017
P2/3, N=450, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> May 2017
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Surgery: The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer (clinicaltrials.gov) - Jan 4, 2017
P2, N=20, Recruiting, Sponsor: Chinese PLA General Hospital
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (clinicaltrials.gov) - Dec 16, 2016
P2/3, N=450, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Dec 2016 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 16, 2016
P2/3, N=110, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Nov 2016 --> Mar 2017
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial primary completion date, Metastases: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 28, 2016
P2/3, N=110, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Nov 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Nov 2016
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open: ADVANCE: ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (clinicaltrials.gov) - Nov 1, 2016
P2, N=103, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Nov 2016 Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Metastases: The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer (clinicaltrials.gov) - Oct 25, 2016
P2, N=30, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Metastases: Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0303? (clinicaltrials.gov) - Sep 20, 2016
P2/3, N=450, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date: ALTER0802: A Study of Anlotinib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 7, 2016
P2, N=60, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: ADVANCE: ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (clinicaltrials.gov) - Aug 21, 2016
P2, N=103, Not yet recruiting, Sponsor: Sun Yat-sen University
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016 Trial primary completion date: Jun 2016 --> Jan 2017
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, P1 data, Metastases: A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients (clinicaltrials.gov) - Jul 7, 2016
P1, N=16, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: ALTER0802: A Study of Anlotinib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 22, 2016
P2, N=60, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- AL2846 / Advenchen, Sino Biopharm
Enrollment open, Metastases: A Study of AL2846 on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Jun 22, 2016
P1, N=20, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Jun 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, P1 data, Metastases: A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - May 26, 2016
P1, N=15, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AL2846 / Advenchen, Sino Biopharm
New P1 trial, Metastases: A Study of AL2846 on Tolerance and Pharmacokinetics (clinicaltrials.gov) - May 20, 2016
P1, N=20, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. (clinicaltrials.gov) - May 18, 2016
P2, N=20, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, P1 data, Metastases: A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) - Apr 27, 2016
P1, N=15, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Enrollment change, Trial primary completion date, Metastases: Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） (clinicaltrials.gov) - Apr 26, 2016
P2, N=133, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Not yet recruiting --> Recruiting N=180 --> 133 | Trial primary completion date: Dec 2015 --> Dec 2016
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy (clinicaltrials.gov) - Apr 26, 2016
P2, N=60, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
N=180 --> 133 | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients (clinicaltrials.gov) - Apr 26, 2016
P1, N=6, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- |||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: Ahead-G201: A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Apr 19, 2016
P4, N=2000, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: A Phase II Study of Anlotinib in STS Patients (clinicaltrials.gov) - Apr 7, 2016
P2, N=200, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Active, not recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Oct 2015
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: ALTN: A Phase II Study of Anlotinib in MTC Patients (clinicaltrials.gov) - Apr 7, 2016
P2, N=47, Active, not recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Trial primary completion date: Feb 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Dec 2016
- AiTan (rivoceranib) / HLB Bio Group
New P2/3 trial, Metastases: Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy (clinicaltrials.gov) - Mar 18, 2016
P2/3, N=37, Recruiting, Sponsor: GUO WEI
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Review, Journal: Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) (clinicaltrials.gov) - Jan 7, 2016
P2, N=144, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, Metastases: Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients (clinicaltrials.gov) - Dec 5, 2015
P1, N=6, Not yet recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial primary completion date: Jan 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Nov 19, 2015
P2/3, N=66, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (clinicaltrials.gov) - Nov 16, 2015
P1/2, N=63, Recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2017 --> May 2017